USS Investment Management Ltd Buys New Stake in BioNTech SE (NASDAQ:BNTX)

USS Investment Management Ltd purchased a new stake in BioNTech SE (NASDAQ:BNTX - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund purchased 27,850 shares of the company's stock, valued at approximately $3,117,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of BNTX. Tema Etfs LLC purchased a new position in shares of BioNTech in the 4th quarter worth $513,000. Stempoint Capital LP purchased a new position in shares of BioNTech in the 4th quarter worth $6,997,000. Shell Asset Management Co. purchased a new position in shares of BioNTech in the 4th quarter worth $2,215,000. Raiffeisen Bank International AG purchased a new position in shares of BioNTech in the 4th quarter worth $1,126,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of BioNTech in the 4th quarter worth $1,014,000. 15.52% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

BNTX has been the subject of a number of recent research reports. HC Wainwright reissued a "buy" rating and issued a $134.00 price objective on shares of BioNTech in a research note on Thursday, May 22nd. BMO Capital Markets boosted their price objective on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research report on Tuesday, March 11th. Citigroup restated a "buy" rating and issued a $140.00 price target (down previously from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. JPMorgan Chase & Co. lowered their target price on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research note on Thursday, May 22nd. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $171.44 price target on shares of BioNTech in a report on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, BioNTech has a consensus rating of "Moderate Buy" and an average target price of $141.73.

BioNTech Stock Performance

NASDAQ BNTX traded down $0.13 on Tuesday, reaching $98.55. 842,090 shares of the company's stock traded hands, compared to its average volume of 919,814. The firm has a market cap of $23.69 billion, a price-to-earnings ratio of -46.93 and a beta of 1.35. The stock has a 50 day moving average price of $97.39 and a 200-day moving average price of $108.38. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.38 by $0.70. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm's quarterly revenue was down 19.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.90 earnings per share. Equities research analysts predict that BioNTech SE will post -3.88 EPS for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.